Another strategy is to target tumor-specific driver mutations that have already occurred in precancerous stages, such as KRAS and EGFR mutations for lung cancer prevention.408–410 These tumor-specific antigens are likely to be more immunogenic with better responses, but clinical trials are required to verify their efficacy and safety. This evidence concerns the gene KRAS and lung carcinoma.